In early 2018, durvalumab became the first immunotherapy to be approved for adjuvant treatment of patients with unresectable stage III non-small cell lung cancer (NSCLC) whose cancer has not progressed after definitive chemoradiotherapy. However, the cost-effectiveness and potential economic implications of using this high-priced therapy in this indication are unknown to date.
F or almost 3 decades, lung cancer death rates for both men and women in the United States have surpassed those of all other cancers. 1 These formidable death rates are driven primarily by a combination of high lung cancer incidence and poor survival outcomes for patients with lung cancer diagnosed in later stages: the 5-year survival rate for patients with distant metastases is approximately 5%. 2 Treatments for advanced-stage lung cancer are seldom curative, with the goal in most cases being to delay progression and maintain quality of life. Recent advances in the use of immunotherapy have led to historical developments in the treatment of advanced non-small cell lung cancer (NSCLC). Singleagent programmed cell death 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) inhibitors and immunotherapy plus chemotherapy combination therapies have demonstrated improvements in overall survival (OS) in both the first-line and secondline settings. [3] [4] [5] [6] [7] [8] [9] [10] [11] The adoption of these treatments as standard therapies in the first and second lines has subsequently spurred efforts to move the use of these agents earlier in the disease course.
Although the therapeutic armamentarium of advanced NSCLC has greatly expanded in recent years, progress for locally advanced, unresectable disease has remained stagnant, with definitive chemoradiotherapy representing the standard of care for more than a decade. Advancements in this area are critical because approximately 0.5 million patients worldwide are diagnosed as having unresectable stage III NSCLC annually, and only 15% of patients who receive chemoradiotherapy are alive after 5 years. 12 Given the success of checkpoint inhibition in later-stage disease, the incorporation of PD-1/PD-L1 inhibition in cases of unresectable stage III NSCLC has become a recent focus. In early 2018, durvalumab, a selective PD-L1 inhibitor, became the first immunotherapy to be approved for adjuvant treatment of patients with unresectable stage III NSCLC whose cancer has not progressed after definitive chemoradiotherapy. 13, 14 The US Food and Drug Administration approved durvalumab based on evidence from the PACIFIC phase 3 randomized clinical trial (ClinicalTrials.gov identifier NCT02125461), 15 in which patients with stage III NSCLC who did not have disease progression after 2 or more cycles of platinum-based chemoradiotherapy were randomized in a 2:1 ratio to receive durvalumab or placebo every 2 weeks for up to 12 months. 14 A preplanned interim analysis published by Antonia and colleagues 14 demonstrated a median progression-free survival (PFS) of 16.8 months for those receiving durvalumab and 5.6 months for those receiving placebo. This statistically significant improvement in PFS (hazard ratio for disease progression or death, 0.52) demonstrated the benefit of immunotherapy in the treatment algorithm of stage III NSCLC and will likely have wide-ranging implications for the treatment of NSCLC more broadly. Given that almost 30% of patients with NSCLC are diagnosed as having stage III disease and the duration of treatment in the adjuvant setting can be up to 1 year, 16 the adoption of durvalumab consolidation therapy after chemoradiotherapy could have a profound financial consequence on cancer treatment spending in the United States. Despite the proven effectiveness of immunotherapy drugs, much concern has been dedicated to the costs associated with these advanced treatments. [17] [18] [19] [20] In 2017, worldwide sales of immunotherapy drugs used for patients with lung cancer surpassed $9 billion, 21-24 with growth projections placing the total market for immunotherapy at $20 to $30 billion in the coming decade.
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With immunotherapy use becoming a standard practice in a continuously increasing number of indications, evaluating the cost-effectiveness of these treatments and projecting their potential budgetary consequences have become instrumental in determining the societal association of implementing these new therapeutic strategies. We aimed to provide a comprehensive economic assessment of durvalumab consolidation therapy after definitive chemoradiotherapy for patients with unresectable stage III NSCLC to better understand its value and budgetary implications at the societal level.
Methods

Simulation Model
To estimate the survival and cost outcomes of patients with unresectable stage III NSCLC without evidence of progression after definitive chemoradiotherapy, we developed a decision analytic microsimulation model in an academic medical setting with a 1-month Markov cycle length that compares different treatment strategies in the context of the US health care system. Given that patients with EGFR mutations made up only 6% of the PACIFIC trial population and other targetable mutations were not studied, these patients were not well represented in the trial and were excluded from our analysis.
14 All simulated patients begin disease free after having received radical treatment with chemoradiotherapy and are followed up as they progress to metastatic disease firstline treatment, metastatic disease second-line treatment, endstage progressive disease, and death, which are all mutually exclusive health states. The main outcome of this study was the incremental cost-effectiveness ratio (ICER) of durvalumab consolidation therapy vs no consolidation therapy, given as aggregate cost of treatment per quality-adjusted life-year gained.
Key Points
Question Is it cost-effective to treat patients with unresectable stage III non-small cell lung cancer whose cancer has not progressed after definitive chemoradiotherapy with durvalumab consolidation therapy?
Findings Using a decision analytic microsimulation model among 2 million simulated patients, this study found that durvalumab in this indication was cost-effective at a $100 000 per QALY willingness-to-pay threshold. Using this treatment strategy for all eligible patients could add an additional $768 million to national cancer spending in year 1; the annual budgetary consequence would then decrease to $241 million in year 5.
Meaning Results of this study suggest that durvalumab consolidation therapy is a cost-effective treatment, although budgetary implications warrant consideration by health policy decision makers.
Patients who survive for more than 5 years without progression are assumed to follow the mean life expectancy for patients with stage III NSCLC who have lived at least 5 years past their date of diagnosis. Age-stratified life expectancies for these patients were determined from a primary data analysis of the Surveillance, Epidemiology, and End Results (SEER)-Medicare database, a population-based cancer registry, and were used to inform survival rates for cured individuals. A 3% annual discount rate was used for survival and cost estimates, and all patients were followed up until death. We estimated ICERs in terms of incremental costs divided by incremental quality-adjusted life-years (QALYs) gained. The ICERs were compared with a $100 000 per QALY willingness-topay (WTP) threshold. 26 This study used only nonidentifiable patient data for secondary data analysis and was approved by Partners Institutional Review Board (protocol 2015P002190).
To reduce the statistical fluctuations of the outcomes, 1 million patients were simulated for each of the following 2 postchemoradiotherapy strategies: (1) all patients receive no additional treatment until progression (no consolidation therapy group) and (2) all patients receive durvalumab consolidation therapy until progression or for a maximum of 1 year (durvalumab consolidation therapy group). This is shown in Figure 1 .
First-line treatment in the metastatic disease state depended on the postchemoradiotherapy strategy used, PD-L1 expression, and tumor histology. Patients were treated with first-line therapy until their disease progressed, at which point they entered metastatic disease second-line treatment ( Figure 2 ). For the purpose of this analysis, cisplatin-based and carboplatin-based treatments were not differentiated in the model because their prices are similarly low and their survival outcomes are not significantly different, 27,28 reflecting common clinical practice in which these drugs are used in similar capacities. Specific details for first-line and second-line treatment strategies are provided in the eMethods in the Supplement. After progression from metastatic disease secondline treatment to end-stage progressive disease, all patients stopped treatment and received best supportive care until death. Additional information on dosing, infusion timing, and patient stratification by PD-L1 expression and histology is listed in eTable 1 in the Supplement. 
Costs
This study evaluated the aforementioned 2 treatment strategies from the societal perspective and thus included the following medical costs associated with cancer treatment: drug acquisition, therapy administration, treatment of major adverse events, follow-up scans, immunohistochemical staining, best supportive care, and death costs. Each of these costs was derived from relevant US sources (eTable 2 in the Supplement). 
Sensitivity Analysis
One-way deterministic sensitivity analyses were performed on model variables to assess the association of uncertainty in variable estimates with the results. For each strategy, 95% CIs or plausible ranges of the selected variables were used, and each variable was tested at the upper and lower limits of its respective interval (eTable 3 in the Supplement). Sensitivity analyses were performed on all model variables; however, only those having meaningful association with cost-effectiveness are presented.
Budgetary Consequence Analysis
In addition to the evaluation of each strategy's costeffectiveness, we conducted a budgetary consequence analysis to project the maximum additional health care spending that would result from fully implementing the durvalumab consolidation therapy strategy in the United States. 40 To find the potential budgetary consequence, we assumed that the durvalumab consolidation therapy strategy was immediately adopted for all eligible patients, defined as those patients with unresectable stage III NSCLC without evidence of progression after definitive chemoradiotherapy. The total number of eligible patients was estimated by multiplying the proportion of patients with NSCLC who were diagnosed in stage III and received chemoradiotherapy based on a SEERMedicare primary data analysis (eTable 4 in the Supplement) by the projected number of annual new cases 2 for 2018 to 2022.
Given that lung cancer incidence is expected to decline in the coming years because of decreasing smoking prevalence in the United States, 41,42 we assumed a 2% decrease in incidence per year. We modeled the undiscounted costs per year for the durvalumab consolidation therapy and no consolidation therapy strategies and then multiplied the mean difference in annual cost between the strategies for each year of treatment by the number of eligible patients. We used a 5-year time horizon (2018-2022), with new eligible patients entering the patient population each year based on expected incidence. Simulated conditions were matched to those of the PACIFIC clinical trial (ClinicalTrials.gov identifier NCT02125461) and reasonable treatment strategies for metastatic NSCLC.
Results
Cost-effectiveness
In the cost-effectiveness analysis, no consolidation therapy after chemoradiotherapy resulted in a mean cost per patient of $185 944 and a mean quality-adjusted survival per patient of 2.34 QALYs. Durvalumab consolidation therapy resulted in a mean cost per patient of $201 563 and a mean qualityadjusted survival per patient of 2.57 QALYs, with an estimated ICER of $67 421 per QALY. 
Sensitivity Analysis
One-way deterministic sensitivity analyses of key variables revealed that the price of durvalumab, price of pembrolizumab, health state utilities, and PFS progression rates most altered the cost-effectiveness of the strategies ( Figure 3 ). Durvalumab consolidation therapy surpassed the $100 000 per QALY WTP threshold in 6 scenarios, as shown in Figure 3 . In addition, the durvalumab consolidation therapy strategy dominated the no consolidation therapy strategy when the price of durvalumab was tested at its lower limit and when the price of pembrolizumab was tested at its upper limit. 
Budgetary Consequence Analysis
Discussion
The approval of durvalumab consolidation therapy for unresectable stage III NSCLC after definitive chemoradiotherapy provides an effective treatment alternative to delay and potentially prevent progression to metastatic disease. Using a microsimulation model, we evaluated the cost-effectiveness of durvalumab consolidation therapy and projected its maximum potential consequence on cancer spending in the United States. We found that durvalumab consolidation therapy was cost-effective compared with no consolidation therapy at a $100 000 per QALY WTP threshold, with an estimated ICER of $67 421 per QALY. The incremental budgetary consequence of using durvalumab consolidation therapy for all eligible patients would be $768 million in year 1 and then decrease to $241 million in year 5. Giving durvalumab earlier in the course of treatment is a cost-effective means of potentially prolonging survival; however, the incremental costs and QALYs associated with durvalumab consolidation therapy vs no consolidation therapy are low. The modest difference between these 2 strategies can be explained by the clinical consequences of immunotherapy combination trials for first-line treatment of metastatic NSCLC, as well as the substantial cost that accompanies long-term immunotherapy use. 44, 45 While durvalumab consolidation therapy is only given for a maximum of 1 year, treatment with pembrolizumab as part of a combination therapy can extend up to 2 years, depending on the response and performance status of the patient, accruing considerable treatment costs and diminishing the cost difference between the 2 strategies. Durvalumab provides a promising opportunity for delaying recurrence and potentially improving the likelihood of cure in a cost- 46 At this rate, approximately $98.3 billion will be spent in 2018 on direct medical costs associated with all cancers, 46 meaning that the projected incremental budgetary consequence in year 1 ($768 million) would correspond to a 0.8% increase. However, cost savings realized in the later years of treatment partially offset the high initial costs of new eligible patients entering the treated population, leading to a lower budgetary consequence over time. Given the anticipated growth in the use of immunotherapy for cancer treatment in the coming years, oncologic spending will undoubtedly increase; therefore, it will be essential for overall affordability to continue to search for indications where these drugs may be used most cost-effectively. Sensitivity analyses showed that the cost-effectiveness of durvalumab consolidation therapy was understandably sensitive to the price of durvalumab. While the base-case analysis showed this treatment strategy to be cost-effective, a decrease in price could minimize uncertainty around its costeffectiveness and greatly reduce its consequence on national cancer spending. In addition, when durvalumab price was tested at its lower limit, the durvalumab consolidation therapy strategy became less costly than the no consolidation therapy strategy. Therefore, a price reduction would lend considerable confidence to durvalumab consolidation therapy being regarded as an economically sound treatment option. Also, testing pembrolizumab price at its upper limit caused durvalumab consolidation therapy to be less costly than no consolidation therapy. This result reinforces the fact that the cost-effectiveness of durvalumab consolidation therapy is dependent on changes in the first-line immunotherapy combination treatments.
Limitations
Our model includes several simplifying assumptions that limit our study. First, since durvalumab consolidation therapy after chemoradiotherapy in patients with stage III NSCLC was approved by the US Food and Drug Administration in February 2018, it is still uncertain what treatment options will be best for patients who progress to metastatic disease. While our basecase analysis represents a likely set of treatment plans, treatment strategies may differ as more becomes known about how patients will respond in later stages. Second, for the purpose of estimating progression rates in our model, we synthesized survival data from multiple clinical trial populations. This introduces uncertainty into our model because no one trial population followed the treatment regimens specified in our model. Third, the number of eligible patients estimated for the budgetary consequence analysis assumes that patients did not progress during chemoradiotherapy, which may have caused the number of patients eligible to be overestimated. Fourth, OS data for the PACIFIC trial have yet to be published, and our study results may be altered if these data show OS to be significantly longer or shorter than modeled in this analysis. If OS in the PACIFIC trial is significantly greater than projected in our model, the cost-effectiveness of durvalumab will likely improve; however, if durvalumab fails to improve OS, it is unlikely that durvalumab will remain cost-effective.
Conclusions
Our study demonstrates that durvalumab consolidation therapy can be cost-effective for patients with unresectable stage III NSCLC whose disease has not progressed after definitive chemoradiotherapy. Given the substantial consequence on cancer spending that immunotherapy treatments will likely have, it is necessary to find indications where these therapies are of most value. Additional efforts should be focused on searching for the patient populations who respond best to immunotherapy and experience the fewest adverse events, potentially through improved biomarker selection, because this will also reduce the overall financial burden imposed by these high-priced therapies. As we learn more about immunotherapy and as subsequent changes to treatment strategies are implemented, cost-effectiveness analyses will allow us to evaluate the association of newly approved indications for immunotherapies with the economics of cancer treatment in the United States and can provide opportunities for more informed discussions on health care policy and planning. 
eMethods. Additional Treatment Strategy Methods
First-Line Treatment Strategy
In the group undergoing no consolidation therapy, patients with tumors that had PD-L1 positivity greater than 50% (high PD-L1 expression) were given first-line pembrolizumab; patients with tumors that had PD-L1 positivity lower than 50% (low PD-L1 expression) and squamous histology received first-line pembrolizumab plus cisplatin or carboplatin (cisplatin/carboplatin) and paclitaxel combination therapy; and patients with low PD-L1 expression and nonsquamous histology were administered first-line pembrolizumab plus cisplatin/carboplatin and pemetrexed. In the durvalumab consolidation therapy strategy, pembrolizumab was not given to any patients as the first-line therapy because all patients had received durvalumab after chemoradiation; patients were given cisplatin/carboplatin and paclitaxel combination therapy if they had squamous histology or cisplatin/carboplatin and pemetrexed if they had nonsquamous histology.
Second-Line and Later Treatment Strategies
In the no consolidation therapy strategy, patients who had received first-line pembrolizumab (high PD-L1 expression patients) were treated with a platinum doublet chemotherapy combination dependent on histology in the second line and then docetaxel in the third line. Low PD-L1 expression patients (both squamous and nonsquamous) were treated with docetaxel in the second line. In the durvalumab consolidation therapy strategy, since all patients had previously received durvalumab, docetaxel was given in the second line, regardless of first-line treatment and histology. Patients were not given additional treatment in the end stage progressive disease setting and were provided with best supportive care. Summarize key study findings and describe how they support the conclusions reached. Discuss limitations and the generalizability of the findings and how the findings fit with current knowledge.
Other
Source of funding 23
Describe how the study was funded and the role of the funder in the identification, design, conduct, and reporting of the analysis. Describe other nonmonetary sources of support.
